Options
A Review on DNA Vaccines in Pre-Clinical Trials Against SARS-CoV-2
Journal
Journal of Experimental Biology and Agricultural Sciences
ISSN
2320-8694
Date Issued
2022-06-26
Author(s)
Dinesh Kumar Lakshmi Narayanan
Shivkanya Fuloria
Saminathan Kayarohanam
Vetriselvan Subramaniyan
Mahendran Sekar
Neeraj Kumar Fuloria
DOI
10.18006/2022.10(3).487.493
Abstract
<jats:p>COVID 19 Pandemic is caused by the viral pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Scientific fraternity worldwide swiftly developed various types of vaccines for the prevention and as mitigation measures for curbing the pandemic. Traditional inactivated vaccines, mRNA vaccines (protein subunits such as spike proteins), and viral vector vaccines (non-replicating vectors with protein subunits) have been approved by World Health Organisation (WHO) for emergency use. The emergence of many mutated variants has been a worrying factor in the fight against the pandemic. There has been continuous research in the quest for more therapeutics, especially vaccines to curb and stop the pandemic. According to WHO, there are 194 vaccines in pre-clinical trials belonging to various types out of which sixteen is DNA vaccines. In this review, we have discussed the advantages and disadvantages of the DNA vaccines for Covid - 19. This article tried to explore the available information on DNA vaccines and their current status against Covid – 19 which are in pre-clinical trials.</jats:p>
File(s)
Loading...
Name
Journal Article.png
Size
17.27 KB
Format
PNG
Checksum
(MD5):85f5e85fa8f8c13d7350540217a227b6
